Top

Category: Mergers and Acquisitions


Mergers and Acquisitions

Asahi Kasei makes $1.1bn bid to buy Calliditas

May 28, 2024

Via: Pharmaphorum

The Japanese group’s tender offer is a premium of around 83% on Calliditas’ closing share price yesterday and has been recommended by the biotech’s board, which says a takeover would enhance its ability to develop and commercialise its products. Calliditas […]


Manufacturing, Mergers and Acquisitions, Research and Development

AGC Biologics and BioConnection Team Up on Biopharma Drug Development and Manufacturing

May 24, 2024

Via: Biopharm International

On May 22, 2024, AGC Biologics and BioConnection, a contract manufacturing organization specializing in aseptic filling of vials and syringes for clinical and commercial production, announced that they have entered into a new strategic partnership. Under the agreement, the companies […]


Industry, Mergers and Acquisitions, Vaccines

Novavax gets a lifeline with Sanofi vaccine pact

May 10, 2024

Via: Biopharma Dive

Allying with Sanofi is a boost for Novavax, which has seen its share price crumble and come under activist investor pressure as it struggles to sell its COVID shot. The company pitched the vaccine as an alternative to the dominant […]


Mergers and Acquisitions

Incyte announces agreement to acquire Escient Pharmaceuticals for $750m

April 24, 2024

Via: PMLiVE

The deal gives Incyte access to an oral Mas-related G protein-coupled receptor X2 (MRGPRX2) antagonist which, according to the companies, “has the potential to treat multiple mast cell-mediated diseases”, including atopic dermatitis, chronic inducible urticaria and chronic spontaneous urticaria. Preclinical […]


Industry, Mergers and Acquisitions, Vaccines

CureVac and MD Anderson Cancer Center partner to develop new cancer vaccines

April 19, 2024

Via: Pharma Times

CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in […]


Industry, Mergers and Acquisitions, Vaccines

Univercells and Andelyn Biosciences Form Separate Drug Development Partnerships

April 3, 2024

Via: Biopharm International

On Mar. 25, 2024 Univercells announced a collaboration with Altamira Therapeutics, a producer of nanoparticle-based technology, under which Univercells will use Altamira’s SemaPhore nanoparticle platform to deliver messenger RNA (mRNA) vaccines. Also on Mar. 25, Andelyn Biosciences, a contract development […]


Mergers and Acquisitions

Lonza Acquires Roche’s US Commercial Biologics Manufacturing Site for $1.2 Billion

March 25, 2024

Via: Biopharm International

Lonza announced on March 20, 2024 that is has signed an agreement to acquire from Roche its Vacaville, Calif., site, a large-scale biologics manufacturing site, for $1.2 billion. Beyond the acquisition, Lonza plans to invest approximately CHF 500 million (US$557 […]


Mergers and Acquisitions

AstraZeneca to acquire Amolyt Pharma, expanding late-stage rare disease pipeline

March 14, 2024

Via: World Pharma News

AstraZeneca announced that it has entered into a definitive agreement to acquire Amolyt Pharma, a clinical-stage biotechnology company focused on developing novel treatments for rare endocrine diseases. The proposed acquisition will bolster the Alexion, AstraZeneca Rare Disease late-stage pipeline and […]


Mergers and Acquisitions

More pharma M&A as Novartis snaps up MorphoSys for $2.9bn

February 6, 2024

Via: Pharmaphorum

The €68-per-share cash offer has been approved by the boards of both companies, who say they expect it to be completed in the latter half of the year, subject to the usual regulatory approvals and other closing conditions. MorphoSys’ share […]


Mergers and Acquisitions

Biovian and 3P Biopharmaceuticals Combine to Form 3PBIOVIAN

February 5, 2024

Via: Biopharm International

Biovian, a contract development and manufacturing organization (CDMO), announced on Feb. 1, 2024 that it was combining with CDMO 3P Biopharmaceuticals to form 3PBIOVIAN under the two companies’ common shareholder, Keensight Capital. The new group, 3PBIOVIAN, will offer end-to-end development […]


Mergers and Acquisitions

Sanofi snaps up Inhibrx and its rare disease drug for $2.2bn

January 23, 2024

Via: Pharmaphorum

France’s Sanofi – a major player in the rare disease category – is offering $30 per share for La Jolla, California-based Inhibrx, which had a closing price of just over $33 yesterday. The cash deal values the company at $1.7 […]


Mergers and Acquisitions

BridgeBio strikes drug royalty deal for cash infusion

January 18, 2024

Via: Biopharma Dive

BridgeBio Pharma has agreed to sell future royalties on an experimental rare disease drug in exchange for $500 million if the medicine, called acoramidis, receives Food and Drug Administration approval. The financing was extended by asset manager Blue Owl Capital […]


Mergers and Acquisitions

Bora Pharmaceuticals Fuels Global Expansion with Acquisition in US

January 17, 2024

Via: Biopharm International

Taiwan’s largest pharmaceutical manufacturer, Bora Pharmaceuticals, has announced the approval by its Board of Directors for the acquisition of generics manufacturer, Upsher-Smith, which is based in Minnesota, USA, for a total of $210 million. According to a Jan. 16, 2024 […]


Mergers and Acquisitions

Körber and Franz Ziel Tighten Ties

December 28, 2023

Via: Biopharm International

There has been speculation around what manufacturing platforms, if any, can consolidate sufficient market share to dominate either specific operations (e.g., fill/finish) or more broadly, a full spectrum production suite of integrated operations. For the foreseeable future at least, it […]


Mergers and Acquisitions

AZ makes another cell therapy play with $1.2bn Gracell buy

December 26, 2023

Via: Pharmaphorum

The agreement is the latest in a series of acquisitions and licensing deals aimed at bolstering AZ’s position in cell therapy, an area where it has lagged behind other companies like Novartis, Bristol-Myers Squibb, and Gilead Sciences, and also continues […]


Mergers and Acquisitions

AZ agrees $1.1bn deal to buy RSV jab developer Icosavax

December 12, 2023

Via: Pharmaphorum

The $15-per-share deal is a 43% premium to Icosavax’s closing share price yesterday and values the company at around $1.1 billion, of which $800 million is payable near-term, with the remainder tied to certain future achievements. It is due to […]


Mergers and Acquisitions

Merck to buy private biotech Caraway in neuroscience deal

November 21, 2023

Via: Biopharma Dive

Caraway raised a small Series A round of $23 million in 2018, backed by several pharmaceutical venture arms, including Merck’s. At the time, the company went by the name of Rheostat Therapeutics. It rebranded to Caraway one year later, but […]


Mergers and Acquisitions

Triveni emerges from biotech merger with $92M for immune disease drugs

October 26, 2023

Via: Biopharma Dive

Triveni sees an opportunity to advance eczema treatment in a similar way to how psoriasis medicines have improved over the past decade, said Vishal Patel, the company’s CEO. In psoriasis, pills like Bristol Myers Squibb’s Sotyktu have joined mainstay biologics […]


Mergers and Acquisitions

Laronde, Senda Biosciences merge to create new Flagship company

October 19, 2023

Via: Biopharma Dive

Sail’s launch ends a difficult period for Laronde, a buzzy Flagship startup that brought in nearly $500 million to fund development of endless RNA-based medicines. Laronde drew investor interest for its work creating synthetic, circular versions of the nucleic acid […]


Mergers and Acquisitions

After summer slump, biotech M&A has a good week

October 10, 2023

Via: Biopharma Dive

This summer, large biotechnology deals took a vacation. In the three-month period from July through September, just six acquisitions worth at least $50 million were announced, according to data compiled by BioPharma Dive. The tally is half of what was […]